Evidence map›Paper›PMID 26111270›Full record

ArticleThe British journal of radiology2015

Use of (99m)Tc-doxorubicin scintigraphy in females with breast cancer: a pilot study.

F I Araujo, F P P Proença, C G Ferreira, S C Ventilari, P H Rosado de Castro, R D Moreira, L M B Fonseca, S A L Souza, B Gutfilen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

F I Araujo1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
F P P Proença2 Nuclear Medicine Section, National Cancer Institute, Rio de Janeiro, Brazil.
C G Ferreira3 Coordination of Clinical Research, National Cancer Institute, Rio de Janeiro, Brazil.
S C Ventilari4 Division of Clinical Oncology, National Cancer Institute, Rio de Janeiro, Brazil.
P H Rosado de Castro2 Nuclear Medicine Section, National Cancer Institute, Rio de Janeiro, Brazil.
R D Moreira3 Coordination of Clinical Research, National Cancer Institute, Rio de Janeiro, Brazil.
L M B Fonseca1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
S A L Souza1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
B Gutfilen1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDoxorubicin (Eurofarma, São Paulo, Brazil) is an antitumour agent widely used in the treatment of breast cancer and can be used for tumour tracking when labelled with a radionuclide. Here, we present the results obtained with technetium-99m ((99m)Tc)-doxorubicin, using the direct method, to evaluate its uptake in breast cancer.

methodsFour females with confirmed breast carcinoma diagnosis and breast image reporting and data system Category 5 on mammography underwent whole-body and thorax single-photon emission CT/CT imaging 1 and 3 h after (99m)Tc-doxorubicin administration.

resultsWe observed increased uptake in breast carcinoma lesions and elimination via renal and hepatic pathways.

conclusionThese preliminary results suggest that (99m)Tc-doxorubicin may be a promising radiopharmaceutical for the evaluation of patients with breast cancer. Further studies are ongoing. ADVANCES IN KNOWLEDGE: To our knowledge, this is the first study to evaluate the use of a directly labelled doxorubicin tracer in humans. (99m)Tc-doxorubicin could provide information on the response of tumours to doxorubicin.

Indexed as

DoxorubicinRadiopharmaceuticalsTechnetiumAdultBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularFemaleHumansMiddle AgedPilot ProjectsRadionuclide ImagingDoxorubicinRadiopharmaceuticalsTechnetium

Identifiers

PMID26111270
PMCPMC4651371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.